News

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...
Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...
Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...
The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...
The study found that GLP-1 medications, in particular, showed significant weight regain after treatment discontinuation.
What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...
Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...
Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
The risks of the new weight-loss drugs can sound scary, and there’s lots of talk about side effects. What does evidence show?
Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...
Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...